Jump to content
  • Welcome to the Rosacea Research and Development Institute [RRDi] official web site. The RRDi is a 501 (c) 3 non profit organization. If you suffer from rosacea you are a rosacean. Join us to find the cure. 

    We are rosaceans. Our non profit organization for rosacea patient advocacy web site is a digital data repository of rosacea information. You can add more information to our web site by joining and posting in our member forum becoming a part of 'finding the cure' for rosacea if you join. Our goal is 10,000 members. You can help us reach our goal by joining

    Where to Begin Your Search
    Community Support • About Us • What Causes Rosacea? • What Should I Ask My Physician?Rosacea NewbiesFamous RosaceansRosacea in the NewsTapatalk • Contact us
    Suggest you read our FAQs for at least a half hour. After that browse our member forum for another half hour. 

    What is Rosacea?
    Rosacea is a chronic and sometimes progressive disorder of the face, characterized by some or all of the following symptoms:

    Extremely sensitive facial skin with blushing, flushing, permanent redness, burning, stinging, swelling, papules, pustules, broken red capillary veins, red gritty eyes (which can lead to visual disturbances) and in more advanced cases, a disfiguring bulbous nose. Men and women of all ages can be affected, with over 415 million estimated rosacea sufferers worldwide

    "Rosacea is probably a collection of many different diseases that are lumped together inappropriately." Zoe Diana Draelos, MD. 
    Dr. Draelos is a member of the ROSIE [ROSacea International Expert] Group that says the subtype classification of rosacea is controversial. Dr. Draelos is also a member of the RRDi MAC. Just because you have a red face might mean you have another skin condition instead of or with rosacea, since other skin conditions may co-exist with rosaceamimic rosacea or you might have a rosacea variant (a dozen variants to differentiate).  

    "Rosacea is a multifactorial, hyper-reactivity, vascular and neural based disease with a broad range of facial manifestations where normal vasodilation is greater and more persistent and involves an autoimmune component of microscopic amounts of extravasated plasma induce localized dermal inflammation that may induce repeated external triggers, vasodilation, telangiectasias, redness with eventual fibrosis and hypertrophic scarring of the dermis." Sandra Cremers, M.D., F.A.C.S., RRDi MAC Member.

    If you note, there are different definitions of what constitutes rosacea which is common. Clarity with phenotypes (see below) helps in a differential diagnosis. 

    Phenotypes
    In November 2016, the RRDi endorsed the phenotype classification of rosacea which was announced by the ROSCO panel as a better approach of diagnosising rosacea than using subtypes.

    Rosacea Differential Diagnosis and Misdiagnosis
    Your physician should differentiate rosacea from a plethora of other skin conditions. If you need photos of rosacea click here.

    Sometimes rosacea is misdiagnosed.

    Treatment
    'There are a number of topical, oral and systemic treatments available. Yet, treatment for rosacea remains difficult." Expert Opinion Pharmacotherapy 

    “There’s no one treatment that’s going to work for everybody, but we evaluate each patient individually and try to select the treatments from our armamentarium that we think will be the simplest and safest for long-term control.” John Meisenheimer, MD, Orlando, The City's Magazine

    ""Ultimately, rosacea is a subjective and entirely individual experience." Rosacea: Beyond the visable

    Cause of Rosacea
    No one really knows what causes rosacea and there are a number of theories for your consideration. Our latest article on this subject, Rosacea Theories Revisited is worth your time to consider. 

    What will the RRDi Do For Me?
    You can view the list of prescription treatments prescribed for rosacea. There is a list of non prescription treatments for rosacea to consider. We have an affiliate store dedicated to rosacea books, treatments and odd and ends. You can browse our public member forum and learn about rosacea. The digital medical revolution can assist you in your search for a treatment to improve your condition. Your rosacea is an individual case and you need to find what treatment will work for your rosacea and not a treatment aimed at the masses. Individuals can come together and share data, using collaboration tools that the RRDi offers for free. If you have the volunteer spirit and want to become part of this innovative non profit, learn how you can volunteer and be part of this digital medical revolution. You can post in our member forum if you join and register simply with an email address. If you have concerns regarding your privacy, please consider this post.

    Once you join you have a number of tools to collaborate with other members. You can create your own rosacea blog, with easy step by step directions on how to do this. Our Gallery application lets members share photos and videos with the community. Volunteers who contribute their time and energy may receive a free G Suite account through a generous contribution of Google, one of our sponsors.  

    You may receive a free ebook, Rosacea 101: Includes the Rosacea Diet as a gift from the founder/director if you mention in your registration application that you want the free ebook (write in the volunteer box you want the free ebook).

    You can post in our member forum about your rosacea experience. However, we want real members, not spammers, hackers or trolls. We provide a safe, secure forum for our members, so our membership registration is very secure requiring your accepting our terms for membership.

    Our 2016 Rosacea Survey is completed and available for public viewing.  You may review a list of our education grants. Finally, ask not what the RRDi can do for you, ask.....

    What Can You Do for the RRDi?
    Your joining and registering with our organization will increase our membership. All that is required to join is an email address (your email address is private and members never see your email address nor does the RRDi give your private email address out to anyone). Our goal is to reach a membership of 10,000 members. Think about that, 10,000 rosacea sufferers joined together as a non profit organization and you are member. We need you to join to help us reach this goal!

    The RRDi is a volunteeer member driven organization and invites rosacea sufferers to become involved. Volunteering is the force that drives the organization and is an integral spirit of the RRDi philosophy. The RRDi warmly invites rosacea sufferers to participate in this non profit which you can become a part of. You are not required to volunteer when you join, since we still want you to join even if you can't volunteer. If all you can do is become a member, that will increase our membership which is helpful in itself. So if you can volunteer, let us know on the application. Please join

    Please carefully read the next subheading on how to join and if you have concerns about privacy. 

    How to Join
    Members may now join with just an email address and a display name (your first and last name is no longer required to be a non voting member and you can set up a anonymous or cryptic display name so that no one knows who you are). To post in our Member Forum or submit articles for publication you must register to join to become a member. The RRDi no longer requires that you provide us with your contact info and mailing address to be a non voting member. However you still need to agree to our policies, rules, etc., since you become a member of the RRDi whether a voting member or not. If you want to vote, simply include all the profile contact fields. We have over 1000 members who are voting members, so we have plenty. It is your choice if you want to vote or not. 

    If you need assistance contact us. Our volunteers will be happy to assist you. 

    Your privacy is our utmost concern and we will take precautions to ensure your privacy will never be violated. Our Privacy Policy is solid. If you have concerns regarding your privacy, please consider this post.

    Once you have joined you can post in our secure members forum which will allow you to post questions to the Medical Advisory Consultants (MAC) and to fellow members or to submit articles for our journal. Yes, members may have an article published on our web site or in our journal. You may receive a free G Suite account with our organization if you have the volunteer spirit. 

    Charter and Mission Statement
    The Charter of the Corporation states the purpose and Mission Statement which clearly outlines the goals of our non profit corporation. If you are interested in the history of how and why this non profit organization was formed click here for more information

    Of course there are expenses to keep this non profit organization going. Any donation you give will assist us to continue to keep this web site going, publish our journal, and sponsor education grantsMahalo for your donation. even if it is small. Every dollar helps us keep going.  

    The RRDi is registered at GuideStar

    guidestorelogo50.pngguidestartransparency50.png

  • Recently Browsing   0 members

    No registered users viewing this page.

  • Who's Online   0 Members, 0 Anonymous, 2 Guests (See full list)

    There are no registered users currently online

  • Member Statistics

    • Total Members
      1,230
    • Most Online
      499

    Newest Member
    Hidalia Felix
    Joined
  • Forum Statistics

    • Total Topics
      4,084
    • Total Posts
      5,245
  • Posts

    • Clinical and erythema-Directed imaging evaluation of Papulo-Pustular rosacea with topical ivermectin: A 32 weeks duration study. J Dermatolog Treat. 2019 Jan 20;:1-15 Authors: Dall'Oglio F, Lacarrubba F, Luca M, Boscaglia S, Micali G Abstract
      BACKGROUND: Ivermectin (IVM) 1% cream represents an emerging therapy for papulo-pustular rosacea (PPR) and erythema-directed photography is a useful tool for evaluation of patient's erythema.
      OBJECTIVE: The aim of our study was to assess the efficacy of IVM in PPR in achieving clear status at 8 weeks and, if unresponsive up to 20 weeks followed by respectively 24 and 12 weeks follow-up, using clinical/instrumental evaluation.
      METHODS: Twenty patients with PPR were instructed to apply IVM for 8 weeks. At week 8, in case of complete response the therapy was stopped and a follow-up period up to 24 weeks was carried out, whereas in case of improvement the treatment was extended for additional 12 weeks followed by a 12 weeks follow-up. Instrumental evaluation was performed by erythema-directed digital photography (VISIA-CRTM- RBXTM).
      RESULTS: At week 8, complete response was observed in 31.6% of cases along with a significant decrease of erythema degree. During treatment extension, additional improvement in terms of complete response, respectively at 12 (42%), 16 (47%) and 20 (58%) weeks, and reduction of erythema degree was observed.
      CONCLUSIONS: IVM is a valuable therapeutic option in mild/moderate PPR. Erythema-directed digital photography enhances erythema changes visualization compared to clinical observation alone.
      PMID: 30663445 [PubMed - as supplied by publisher] {url} = URL to article
    • image courtesy of Cognitune "Turmeric can even help prevent acne, cancer, allergies, diabetes, joint pain, and depression." 10 Health Benefits and Uses for Turmeric Curcumin Supplements, Cognitune Smarter Health
    • RedMage, 
      This paper is not a double blind, placebo controlled study on rosacea and diet. As it explains, it was "collected by standardized questionnaires." So the results are based upon anecdotal reports, and none of these 'patients with rosacea' were in a clinical laboratory with controls on what they ate and drank. They simply answered questions on a form. How can anyone be sure that the patients answered correctly or omitted pertinent data?  While the data collected may be helpful, since there are rarely any papers on diet and rosacea, at least they have made an attempt at the task which is monumental, and the paper is interesting, to say the least.   So when the report says "high-frequency dairy product intake showed negative correlations with ETR and papulopustular rosacea" does it differentiate between ice cream with heavy amounts of sugar or just plain heavy cream without sugar?  There is a big difference. If you took one hundred rosaceans and had them just eat heavy cream for a week and see the results with another group that just ate ice cream for a week you might notice differences. Or compare one hundred rosaceans eating just cheese for a week with a group of a hundred rosaceans who just eat milk shakes.  As for the fatty food and tea, again, there really aren't any controls, and the data could be biased since it is anecdotal. Possibly the one good item about this report is that it may stimulate more papers on diet and rosacea. Most rosaceans have a gut feeling about their rosacea, while other rosaceans report that diet has no effect on their rosacea.  A real clinical study on rosacea and diet hasn't been done yet. Wouldn't it be something if a non profit organization for rosacea patient advocacy could get 10,000 rosacea sufferers together into one group and conduct their own research (say each one donated $1) on diet and rosacea. 
    • Does it mean that for ETR we should eat dairy based food and cut any fatty food and tea?    
    • Related Articles Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2018 Dec 28;: Authors: Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A Abstract
      BACKGROUND: Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.
      OBJECTIVES: To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.
      METHODS: Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.
      RESULTS: Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.
      CONCLUSIONS: These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study.
      PMID: 30658871 [PubMed - as supplied by publisher] {url} = URL to article
    • Related Articles Sarecycline: First Global Approval. Drugs. 2019 Jan 18;: Authors: Deeks ED Abstract
      Sarecycline (Seysara™) is an oral, once-daily, tetracycline-class drug for which a tablet formulation is approved in the USA for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥ 9 years. The drug was developed by Paratek and Allergen and later acquired by Almirall S.A. (a Barcelona-based pharmaceutical company focused on medical dermatology). Sarceycline tablets were approved in early October 2018 and are planned to be available for patients in January 2019. Sarecycline capsules have also been studied in the USA, but no recent reports of development have been identified for this formulation. There are currently no clinical trials underway assessing sarecycline in rosacea. This article summarizes the milestones in the development of sarecycline leading to this first approval for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
      PMID: 30659422 [PubMed - as supplied by publisher] {url} = URL to article
×